Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.

Kenshi SuzukiChang-Ki MinKihyun KimJe-Jung LeeHirohiko ShibayamaPo-Shen KoShang-Yi HuangSin-Syue LiBifeng DingMonica KhuranaShinsuke Iida

Published in: International journal of hematology (2021)

There was a trend toward better efficacy and a favorable benefit-risk profile for KdD vs Kd in Asian patients with RRMM. Cautious interpretation is warranted due to small patient size.

Keyphrases

multiple myeloma
phase iii
study protocol
clinical trial
case report
low dose
high dose
phase ii
open label
randomized controlled trial
hodgkin lymphoma